INT J CANCER 润色咨询

INTERNATIONAL JOURNAL OF CANCER

出版年份：暂无数据 年文章数：9003 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2023-03-31 Linyan Yu 来自山东省

    偏重的研究方向：肿瘤相关;Environmental Research
    经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-12-08 yousuosaki 来自海南省

    偏重的研究方向：mutational signature
    经验分享：2022.09.02 submitted
    2022.09.04 under evaluation
    2022.09.12 under review
    2022.09.20 under evaluation
    2022.09.21 under review
    2022.10.20 awaiting decision
    2022.10.25 major revision
    2022.11.19 resubmission
    2022.11.21 under review
    2022.12.2 under evaluation
    2022.12.6 under review
    2022.12.7 awaiting decision
    2022.12.8 accepted

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-04-26 ms9000000399989409

    偏重的研究方向：肿瘤;Cancer;临床
    经验分享：问一下大家under evaluation都持续几天呢?

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2023-03-21 ms3000001615675881 来自弗吉尼亚

    请问一般under evaluation几天呀，已经10天了

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2020-09-04 Nevermorx

    有没有人投综述呀

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-08-23 ms2000002114558983

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤;微生物
    经验分享：3.24咨询是否接收散稿；
    3.28回复感兴趣，欢迎投稿；
    3.31投稿；
    4.4under review;
    4.27major revisions；
    6.20修回；
    6.21外审；
    7.13major revisions；
    8.11修回后决定；
    8.15接收。
    过程很艰辛，审稿人很专业，要求比较高。

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-08-27 ms5000001852951271

    偏重的研究方向：肿瘤;biomarker
    经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-04-08 ms9000000300158487

    偏重的研究方向：tumor microenironment
    经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2022-11-12 capoex

    投稿命中率:25.0
    偏重的研究方向：实体肿瘤
    经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2122992, encodeId=d2fa21229924d, content=偏重的研究方向：肿瘤相关;Environmental Research<br>经验分享：请问一下大家，投稿IJC的时候单细胞测序数据必须上传到数据库中吗？还是说等文章确定接收了再上传也行？细胞系鉴定证明有没有模板分享一下？不胜感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a55725098, createdName=Linyan Yu, createdTime=Fri Mar 31 18:59:13 CST 2023, time=2023-03-31, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2104984, encodeId=504d21049849d, content=偏重的研究方向：mutational signature<br>经验分享：2022.09.02 submitted<br>2022.09.04 under evaluation<br>2022.09.12 under review<br>2022.09.20 under evaluation<br>2022.09.21 under review<br>2022.10.20 awaiting decision<br>2022.10.25 major revision<br>2022.11.19 resubmission<br>2022.11.21 under review<br>2022.12.2 under evaluation<br>2022.12.6 under review<br>2022.12.7 awaiting decision<br>2022.12.8 accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c358198965, createdName=yousuosaki, createdTime=Thu Dec 08 21:00:04 CST 2022, time=2022-12-08, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床<br>经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240598, encodeId=ec351240598a6, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;微生物<br>经验分享：3.24咨询是否接收散稿；<br>3.28回复感兴趣，欢迎投稿；<br>3.31投稿；<br>4.4under review;<br>4.27major revisions；<br>6.20修回；<br>6.21外审；<br>7.13major revisions；<br>8.11修回后决定；<br>8.15接收。<br>过程很艰辛，审稿人很专业，要求比较高。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6235708552, createdName=ms2000002114558983, createdTime=Tue Aug 23 21:53:36 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker<br>经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209671, encodeId=2d0612096e128, content=偏重的研究方向：tumor microenironment<br>经验分享：2022-3-27 submit，当天under evaluation，现在还是此状态，愁了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2995720940, createdName=ms9000000300158487, createdTime=Fri Apr 08 21:13:08 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100157, encodeId=35b5210015e22, content=投稿命中率:25.0<br>偏重的研究方向：实体肿瘤<br>经验分享：刚投了两天，投完很快状态变为Under evaluation，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201116/55827511442747d6a2c4eddf1b90c605/90d61936952348a1809c9ff037c4101f.jpg, createdBy=d5bb5260460, createdName=capoex, createdTime=Sat Nov 12 20:53:58 CST 2022, time=2022-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海)]
    2023-02-18 1475fbf4m67暂无昵称 来自上海

    偏重的研究方向：Cancer
    经验分享：请问这个杂志接收生信和试验结合的临床文章嘛

    1

    展开1条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分